Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis

ContextCabozantinib combined with immune checkpoint inhibitors (ICIs) has brought a new therapeutic effect for the medical treatment of renal cell carcinoma (RCC).ObjectivesWe performed a meta-analysis of randomized controlled trials and single-arm trials to evaluate the efficacy and safety of caboz...

Full description

Bibliographic Details
Main Authors:	Jingyang Su, Jialin Zhang, Yuqian Wu, Cui Ni, Yueyue Ding, Zelin Cai, Ming Xu, Mingyang Lai, Jue Wang, Shengyou Lin, Jinhua Lu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Series:	Frontiers in Pharmacology
Subjects:	renal cell carcinoma cabozantinib tyrosine kinase inhibitors immune checkpoint inhibitors adverse events
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1322473/full

Similar Items

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
by: Jeffrey Sum-Lung Wong, et al.
Published: (2021-04-01)

Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study
by: Piotr Domański, et al.
Published: (2024-02-01)

Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis
by: Yao-Ning Feng, et al.
Published: (2023-06-01)

Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
by: Koji Iinuma, et al.
Published: (2022-12-01)

Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
by: Stefania Kokkali, et al.
Published: (2023-01-01)

ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA)
by: Tarini Prasad Sahoo, et al.
Published: (2023-08-01)

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
by: Linnea Højer Wang, et al.
Published: (2023-01-01)

Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b<sub>5</sub> Activity
by: Radek Indra, et al.
Published: (2020-11-01)

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial
by: Francesca Corti, et al.
Published: (2023-09-01)

Cabozantinib: A narrative drug review
by: Vivek K Srigadha, et al.
Published: (2023-01-01)

Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials
by: Patrick L. Sweeney, et al.
Published: (2022-01-01)

Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?
by: Estelle Granet-Vaissiere, et al.
Published: (2023-02-01)

Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report
by: Veronika Blum, et al.
Published: (2022-12-01)

Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective
by: Daniele Lavacchi, et al.
Published: (2020-06-01)

Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients—Real-World Experience in a Single-Center Retrospective Study and Narrative Review
by: Piotr Domański, et al.
Published: (2024-02-01)

Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
by: Takuto Shimizu, et al.
Published: (2024-02-01)

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
by: Silvia Carra, et al.
Published: (2021-03-01)

Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results
by: Alessandro Comandone, et al.
Published: (2021-11-01)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
by: Michele Iuliani, et al.
Published: (2021-08-01)

Effect of galectin‐1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma
by: Jiajun Wang, et al.
Published: (2024-04-01)

Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications
by: Eleonora Lauricella, et al.
Published: (2022-08-01)

Management of Toxicity and Side Effects of Systemic Therapy for Renal Cell Carcinoma
by: Kate Young, et al.
Published: (2022-11-01)

Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis
by: Xiangyu Chen, et al.
Published: (2024-02-01)

The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma
by: Stephanie A. Berg, et al.
Published: (2022-12-01)

The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma
by: Shou-Wu Lee, et al.
Published: (2022-08-01)

Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review
by: Vito Longo, et al.
Published: (2019-04-01)

Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma
by: Yasir Khan, et al.
Published: (2020-12-01)

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
by: Zoé Guillaume, et al.
Published: (2022-03-01)

A case of an advanced renal collecting duct carcinoma in which initial therapeutic effect was achieved with pembrolizumab plus axitinib
by: Yuichiro Atagi, et al.
Published: (2024-01-01)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
by: Christopher Kwok, et al.
Published: (2023-07-01)

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab
by: Maciej Niewada, et al.
Published: (2023-03-01)

Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma
by: Satoru Takahashi, et al.
Published: (2022-08-01)

Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
by: Federica Cosso, et al.
Published: (2023-02-01)

Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma
by: Hodaka Yamada, et al.
Published: (2022-04-01)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
by: Huang JT, et al.
Published: (2022-11-01)

The Changing Therapeutic Landscape of Metastatic Renal Cancer
by: Javier C. Angulo, et al.
Published: (2019-08-01)

Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience
by: Pan X, et al.
Published: (2023-06-01)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
by: Bersanelli M, et al.
Published: (2018-09-01)

Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma
by: Rosa Maria Paragliola, et al.
Published: (2023-01-01)

Efficacy and Synergy of Small Molecule Inhibitors Targeting <i>FLT3</i>-ITD<sup>+</sup> Acute Myeloid Leukemia
by: Javier Bregante, et al.
Published: (2021-12-01)